Restoration of chemosensitivity by bortezomib: implications for refractory myeloma
- 1 April 2009
- journal article
- case report
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 6 (4), 237-240
- https://doi.org/10.1038/nrclinonc.2009.15
Abstract
Resistance to chemotherapy remains one of the major challenges in the treatment of patients with multiple myeloma. Chim et al. report the case of a 59-year-old woman with multiple myeloma, who progressed after treatment with conventional chemotherapeutic agents. Addition of bortezomib to her treatment regimen resulted in complete regression of her disease. The authors suggest that bortezomib can restore chemosensitivity of myeloma cells in heavily pretreated, chemorefractory patients with multiple myeloma. Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow transplantation, and 14 months later she developed obstructive jaundice. Investigations. Serum protein electrophoresis, contrast CT of thorax and abdomen, endoscopic retrograde cholangiopancreatography with endoscopic biopsy and pleural biopsy. Diagnosis. Extramedullary plasmacytomas at pancreatic head and pleura. Management. Salvage chemotherapy regimens including bortezomib plus steroid, alkylators plus steroid, bortezomib plus anthracycline and radiotherapy, and combined bortezomib, cyclophosphamide, melphalan and steroid therapy.Keywords
This publication has 16 references indexed in Scilit:
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood, 2006
- Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myelomaEuropean Journal of Haematology, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Multiple MyelomaNew England Journal of Medicine, 2004
- Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosisBlood, 2004
- Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytomaBritish Journal of Haematology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.Journal of Clinical Oncology, 1998
- Combination Chemotherapy for Multiple Myeloma with BCNU, Cyclophosphamide, Vincristine, Melphalan, and Prednisone (M-2 Protocol)Oncology, 1985